Skip to main content
Premium Trial:

Request an Annual Quote

Response Secures $12M Credit Facility

NEW YORK (GenomeWeb) – Response Genetics and SWK Funding today announced a credit agreement to provide Response with a term loan of up to $12 million.

Response has drawn the first tranche of $8.5 million of the new credit facility. A second tranche is conditional on the Los Angeles-based molecular diagnostics firm achieving a certain revenue milestone.

In a statement, Response Chairman and CEO Thomas Bologna said the proceeds from the financing will go toward growth initiatives including the commercialization of the newly launched ResponseDX: Tissue of Origin test, which the company acquired through its purchase last year of certain assets of Pathwork Diagnostics; its technical component/professional component testing service, in which Response processes a patient's sample while a pathologist interprets the results; and the Comprehensive Lung Profile service, which incorporates next-generation sequencing with fluorescence in situ hybridization and RNA biomarkers.

In connection with the closing of the first tranche, Response issued to SWK Funding, a wholly owned subsidiary of SWK Holding, a warrant to purchase an aggregate of 681,090 shares of common stock at an exercise price of $.936 per share. The loan matures on July 29, 2020, and accrues interest at an annual rate of 12.5 percent plus the Libor Rate.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.